The Pillars for Sustained Growth of Magnetic Resonance Imaging Pathway for Prostate Cancer Diagnosis: Quality, Reproducibility, Accessibility, Cost Effectiveness, and Training (European Urology)
In contrast to most other solid organ malignancies, the diagnosis of prostate cancer (PCa) is typically made with systematic biopsy (SBx), following a prescribed, but random, pattern of gland sampling. SBx is subject to systematic and random errors leading to missampling or misclassification of PCa; therefore, a more accurate diagnostic strategy is required [1]. Multiparametric magnetic resonance imaging (mpMRI) for PCa assessment has evolved. Initially used for local staging prior to definitive treatment, mpMRI is now being used prior to prostate biopsy (PBx) to identify and guide targeted biopsy (TBx) of lesions suspicious for clinically significant PCa (CSPCa) [2].